MICRO-X LIMITED (MX1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MX1 - MICRO-X LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.30

15 Sep
2021

0.000

OPEN

$0.30

0.000

HIGH

$0.31

479,859

LOW

$0.30

TARGET
$0.58 93.3% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
MX1: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx - 3.7 - 2.7 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx-3.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx3.8 M
Book Value Per Share xxxxxxxxxxxxxxx7.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-9.9 M
Net Profit Margin xxxxxxxxxxxxxxx-390.64 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx-37.59 %
Return on Equity xxxxxxxxxxxxxxx-60.27 %
Return on Total Capital xxxxxxxxxxxxxxx-46.34 %
Capex xxxxxxxxxxxxxxx0.9 M
Capex % of Sales xxxxxxxxxxxxxxx23.89 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.6 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

15/09/2021

1

Add

$0.58

93.33%

Morgans assesses there is an opportunity in Micro-X, when comparing its technology and commercial outcomes with the US-based Nanox which operates in a similar segment.

Both are developing technology to militarise x-rays, with applications not only in hospitals but also in security and military settings.

Micro-X has also received Australia's Therapeutic Goods Authority approval for the Rover and the company estimates the market size is $10m. Morgans maintains a positive stance on the stock and the Speculative Buy rating is maintained. Target is $0.58.

FORECAST
Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -2.70 cents.
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -0.90 cents.

MX1 STOCK CHART